Systematic Review and Meta-Analysis of Outcomes of Soluble Guanylate Cyclase Stimulators in Patients With Heart Failure

May 15-17, 2021; Virtual
In patients with heart failure, sGC stimulators reduced risk of a combined endpoint including cardiovascular death and hospitalization for heart failure in individuals with reduced ejection fraction but had no benefit in those with preserved ejection fraction.
Format: Microsoft PowerPoint (.ppt)
File Size: 326 KB
Released: June 28, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

Dr. Lee R. Goldberg discusses key studies from ACC 2021 that will impact heart failure management, as reported by Clinical Care Options (CCO)

Lee R. Goldberg, MD, MPH, FACC Released: July 15, 2021

From Clinical Care Options (CCO) and Dr. James Udelson, expert commentary on new data in heart failure management from ACC 2021

James Udelson, MD Released: July 14, 2021

From Clinical Care Options (CCO), new data from ACC 2021 on SGLT2 inhibitors in heart failure

Released: July 1, 2021

Latest data on cardiac rehabilitation in patients with heart failure with preserved ejection fraction from ACC 2021 reported by Clinical Care Options (CCO)

Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue